El aumento de la actividad proinflamatoria es consustancial a la resistencia a la insulina

Medicina Clinica

Volumn 115, Issue 5, 2000, Pages 185-189

  Fernández Real, José Manuel ^a   Ricart, Wilfredo ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; INSULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANIMAL; CARBOHYDRATE METABOLISM; CELL CULTURE; CYTOLOGY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADIPOCYTES; ADIPOSE TISSUE; ADULT; ANIMALS; CARBOHYDRATE METABOLISM; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; ISLETS OF LANGERHANS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, OBESE; MUTATION; OBESITY; POLYMORPHISM, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034221809     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71502-8     Document Type: Article

References (77)

1. Shen S-W, Reaven GM, Farquhar JW. Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest 1970; 49: 2151-2160.
2. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
3. Reaven GM, Hollenbeck CB, Chen Y-DI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 1989; 32: 52-55.
4. Laws A, Stefanick ML, Reaven GM. Insulin resistance and hipertriglyceridemia in nodiabetic relatives of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69: 343-347.
5. Ho LT, Chang ZY, Wang JT, Li SH, Liu YF, Chen YD et al. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med 1990; 7: 31-34.
6. Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987; 64: 1169-1173.
7. Reaven GM, Brand RJ, Chen Y-DI, Mathur AK, Goldfine I. Insulin resistane and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 1993; 42: 1324-1332.
8. a ed.). Nueva York: WH Freeman, 1995; 603-628.
9. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
10. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce M et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
11. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. Leptin levels in human and rodent: measuement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161.
12. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation of obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.
13. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
14. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T et al. Enhanced expression of PAI-I in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
15. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS. Tissue-especific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
16. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992; 267: 12736-12741.
17. Donahue WT, Eckel RH. Adipocyte metabolism in obesity. Curr Opin Endocrinol Diab 1996; 3: 501-507.
18. DeFronzo RA. Lilly Lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
19. Reaven GM. The fourth Musketeer - from Alexander Dumas to Claude Bernard. Diabetologia 1995; 38: 3-13.
20. Jeng C-Y, Sheu WH-H, Fun MM-T, Cheng Y-DI, Reaven GM. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes 1994; 48: 1440-1444.
21. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
22. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-plasma protein genes. Mol Cel Biol 1992; 12: 1789-1797.
23. O'Riordain MG, Ross JA, Fearon KCH, Maingay J, Farouk M, Garden OJ et al. Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol 1995; 269: E323-E330.
24. Fernández Real JM, Grasa M, Casamitjana R, Pugeat M, Barret C, Ricart W. Plasma total and glycosylated corticosteroid binding globulin (CBG) levels are associated with insulin secretion. J Clin Endocrinol Metab 1999; 84: 3192-3196.
25. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expession of TNFa by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 97: 1111-1116.
26. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha. and obesity-induced insulin resistance. Science 1996; 271: 665-668.
27. Cryer A. Comparative biochemistry and physiology of lipoprotein lipase En: Borensztajn J, editor. Lipoprotein lipase. Chicago: Evener, 1987; 277-327.
28. Norman RA, Bogardus C, Ravussin E. Linkage-between obesity and a marker near the tumor necrosis factor-α locus in Pima Indians. J Clin Invest 1995; 96: 158-162.
29. Fernández-Real J, Gutiérrez C, Ricart W, Casmitjana R, Vendrell J, Fernández-Castañer M et al. The TNF-α Nco I polymorphysm influences the relationship among insulin resistance, percent body fat and increased serum leptin levels. Diabetes 1997; 46: 1468-1472.
30. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumour necrosis factor alpha prometer on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
31. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A et al. Polymorphisms of the tumour necrosi factor-α gene, coronary heart disease and obesity. Eur J Clin Invest 1998; 28: 59-66.
32. McGuire W, Hill VS, Allsopp EM, Greenwood BM, Kwaitkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-511.
33. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Commun 1995; 211: 833-839.
34. Fernández-Real JM, Gutiérrez C, Ricart W, Casamitjana R, Broch M, Vendrell J et al. A TNF-α gene Nco I polymorphism is not associated with hypertrygliceridemia or insulin resistance in lean and obese subjects. Biochem Biophys Res Comm 1997; 236: 829-832.
35. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 Tumor Necrosis Factor Receptor in human obesity and insulin resistance. Diabetes 1997; 46: 451-455.
36. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151-153.
37. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76: 959-962.
38. Nophar Y, Kemper O, Brakebusch C, Engleman H, Zwang R, Aderlka D et al. Soluble forms of tumor necrosis factors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269-3278.
39. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329.
40. Fernández-Real JM, Gutiérrez C, Broch M, Casamitjana R, Vendrell J, Ricart W. The Insulin response to intravenous glucose correlates with plasma levels of the tumor necrosis factor receptor-1. Diabetes Care 1999; 22: 868-870.
41. Fernández-Real JM, Broch M, Ricart W, Broch M, Casamitjana R, Vendrell J et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998; 47: 1757-1762.
42. Fernández-Real JM, Molina A, Broch M, Ricart W, Gutiérrez C, Casamitjana R et al. The TNF system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes 1999; 48: 1108-1112.
43. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H. Selective upregulation of the 75-kDA tumor necrosis (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 1993; 150: 4346-4353.
44. Neel JV. Diabetes mellitus: a «thrifty» genotype rendered detrimental by «progress». Am J Hum Genet 1962; 14: 353-362.
45. Reaven GM. Hypothesis: muscle insulin resistance is the («not-so») thrifty genotype. Diabetologia 1998; 41: 482-484.
46. Eaton SB, Konner M. Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med 1985; 312: 283-289.
47. Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am J Med 1988; 84: 739-749.
48. Pedersen BK, Niemann DC. Exercise immunology: integration and regulation. Immunol Today 1998; 19: 204-206.
49. Schreyer SA, Chua SC, LeBoeuf RC. Obesity and diabetes in TNF-alfa receptor-deficient mice. J Clin Invest 1998; 102: 402-411.
50. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998; 8: 335-338.
51. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J et al. Endotoxin and cytokines induce expresion of leptin, the ob gene product, in hamsters. A role for leptin in the anorexia of infection. J Clin Invest 1996; 97: 2152-2157.
52. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-α contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997; 100: 2777-2782.
53. Qian H, Hasman GJ, Compton MM, Azain MJ, Hartzell DL, Baile CA. Leptin regulation of peroxisome proliferator-activated receptor-gamma, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues. Biochem Biophys Res Commun 1998; 246: 660-667.
54. Zumbach MS, Boehme MW, Wahl P, Stremmel W, Ziegier R, Nawroth PP. Tumor necrosis factor increrases serum leptim levels in human. J Clin Endocrinol Metab 1997; 82: 4080-4082.
55. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans. J Clin Endocrinol Metab 1997; 82: 3408-3413.
56. Fernández-Real JM, Vendrell J, Ricart W, Broch M, Gutiérez C, Casamitjana R et al. A polymorphism of the tumor necrosis factor receptor-2 gene is associated with obesity, leptin levels and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000; 24:
57. Orban Z, Remaley A, Sampson M, Trajanoski Z, Chrousos GP. The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999; 84: 2126-2133.
58. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850.
59. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
60. Papanicolau DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
61. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
62. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow WO, Jablons D. Interleukin-6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin-6 in cancer cachexia. Cancer Res 1992; 52: 4113-4116.
63. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136: 2143-2149.
64. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995; 268: E813-E819.
65. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al. The effect of novel polymorphisms in the interleukin 6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
66. Fernández-Real JM, Broch M, Vendrell J, Richard C, Ricart W. Interleukin 6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85: 1334-1339.
67. Mendall MA, Pate P, Asante M, Ballam L, Morris J, Strachan DP et al. Relation of serum cytokine concentraton to cardiovascular risk factors and coronary artery disease Heart 1997; 78: 273-277.
68. Baggio G, Donazzan S, Monti D, Man D, Martini S, Gabelli C et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998; 12: 433-437.
69. Starnes HH Jr, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF et al. Tumor necrosis factor and the acute metabolic response to injury in man J Clin Invest 1988; 82: 1321-1325.
70. Fernández-Real JM, Gutiérrez C, Ricart W, Castiñeira MJ, Vendrell J, Ricart W. Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis 1999; 146: 321-327.
71. Fernández-Real JM, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M et al. Interleukin 6 gene polymorphism and insulin sensitivity. Diabetes 2000; 49 517-520.
72. Facchini F, Hollenbeck CB, Chen YN, Chen YD, Reaven HM. Demonstration of a relationship between white blood cell count, insulin resistance, and several risk factors for coronary heart disease in women. J Intern Med 1992; 232: 267-272.
73. Targher G, Seidell JC, Tonoli M, Muggeo M, De Sandre G, Cigolini M. The white blood cell count: its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. J Intern Med 1996; 239: 435-441.
74. Romani L, Mencacci A, Cenci E, Spaccapelo R, Toniatti C, Puccetti P et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin-6-deficient mice infected with Candida albicans. J Exp Med 1996; 183: 1345-1355.
75. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF et al. IL-6 is an antiinflammatory cytokine requiered for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-320.
76. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512.
77. Fernández-Real JM, Ricart W. Insulin resistance and inflammation. The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999; 42: 1367-1374.